Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

633
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
633
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

529
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
529
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

20
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
20
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

734
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
734
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

31
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
31

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRISPR Gene Tagging for Illuminating Endogenous Protein Dynamics.

International journal of molecular sciences·2026
Same author

Rescuing the Function of Missense-Mutated Tumor Suppressor <i>VHL</i> using Stabilizing Small Molecules.

bioRxiv : the preprint server for biology·2026
Same author

Correction to "Potent, Selective Pyrrolopyrimidine PDE11A4 Inhibitors with Improved Pharmaceutical Properties".

ACS medicinal chemistry letters·2026
Same author

A fission yeast-based platform for nematode PDE inhibitor discovery.

Cellular signalling·2026
Same author

P2X7R-mediated IL-1β release by human brain tissue: the impact of CNS-penetrant potential therapeutics.

Brain : a journal of neurology·2026
Same author

Age-Related Upregulation and Strong Expression Correlation of the Proinflammatory Cytokines IL-1β and IL-6 Across Multiple Segments of the Mouse Eye.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Feb 19, 2026

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

7.1K

Potent, Selective Pyrrolopyrimidine PDE11A4 Inhibitors with Improved Pharmaceutical Properties.

Shams Ul Mahmood1, Rama Krishna Boddu1, Jeremy Eberhard2

  • 1Department of Chemistry and Biochemistry, Sokol Institute of Pharmaceutical Life Sciences, Montclair State University, Montclair, New Jersey 07043, United States.

ACS Medicinal Chemistry Letters
|February 18, 2026
PubMed
Summary

Researchers optimized a pyrrolopyrimidine compound to create a potent phosphodiesterase 11A4 (PDE11A4) inhibitor. This new inhibitor shows improved pharmaceutical properties and promising cell-based activity for future studies.

Keywords:
LLPS activityPDE11A4cell-based activitypharmaceutical propertiesphosphodiesterase inhibitor

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.4K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Related Experiment Videos

Last Updated: Feb 19, 2026

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

7.1K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.4K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Enzyme Inhibition

Background:

  • Previous research identified a potent, orally bioavailable phosphodiesterase 11A4 (PDE11A4) inhibitor targeting the mouse hypothalamus.
  • The prior inhibitor exhibited low aqueous solubility, hindering further efficacy studies and necessitating new lead compounds.
  • Improved pharmaceutical properties are crucial for advancing PDE11A4 inhibitors into preclinical and clinical development.

Purpose of the Study:

  • To optimize a pyrrolopyrimidine hit compound into a potent and selective PDE11A4 inhibitor.
  • To enhance the pharmaceutical properties, particularly aqueous solubility, of the lead compound.
  • To evaluate the activity of the optimized inhibitor in cell-based models.

Main Methods:

  • Structure-based drug design and medicinal chemistry optimization of a pyrrolopyrimidine scaffold.
  • In vitro biochemical assays to assess potency and selectivity against PDE11A4.
  • Physicochemical property assessments, including aqueous solubility.
  • Cell-based assays to evaluate enzyme activity and cellular efficacy.

Main Results:

  • Successful optimization of the pyrrolopyrimidine hit resulted in a highly potent and selective PDE11A4 inhibitor.
  • The optimized compound demonstrated significantly improved aqueous solubility and other favorable pharmaceutical properties compared to the previous lead.
  • The new inhibitor exhibited promising activity in cell-based models, confirming its potential for further investigation.

Conclusions:

  • The optimized pyrrolopyrimidine derivative represents a promising new chemical entity for PDE11A4 inhibition.
  • This compound overcomes the solubility limitations of previous inhibitors, enabling further efficacy studies.
  • The findings support the therapeutic potential of targeting PDE11A4 with optimized small molecules.